Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services Thursday, February 25, 2016 Ubiquigent has announced that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams to deliver an even more comprehensive range of services to the global life science research community. Powerful Drug for Familial Amyloidosis Thursday, February 25, 2016 The molecule has proved in preclinical trials to be up to four times more effective than the only pharmacological treatment currently available for familial transthyretin amyloidosis, a rare degenerative disease, and has already been tested in a clinical trial with patients.Plasticell and Pierre Fabre Laboratories Sign a Partnership Wednesday, February 24, 2016 Company has announced collaboration to identify natural stimulants of brown fat for treatment and prevention of obesity and diabetes.HIV Modification May Put a Twist on Vaccine and Drug Design Wednesday, February 24, 2016 Crucial HIV RNA modification called m6A influences viral replication, but wasn’t previously taken into consideration when developing anti-HIV therapies.Rapid, Highly Sensitive Diagnostics Tuesday, February 23, 2016 A portable and low-cost diagnostic device has been developed at EPFL. This microfluidic tool, which has been tested with Ebola, requires no bulky equipment. It is thus ideally suited for use in remote regions.Secret to Promising New Cancer Drug Discovered Tuesday, February 23, 2016 Researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment.BioAgilytix Acquires IPM Biotech Tuesday, February 23, 2016 BioAgilytix has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity. Myriad Expands Collaboration with TESARO, Merck Tuesday, February 23, 2016 Companion diagnostic portfolio to evaluate treatment response in patients with triple negative breast cancer or ovarian cancer.Axol Appoints Paul Andrews to Scientific Advisory Board Tuesday, February 23, 2016 Phenotypic drug discovery expert joins the stem cell disease model specialists.